Standard BioTools Inc LAB
📋 Company Profile
| Industry | Life Sciences Tools & Services |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2011-02-10 |
| Shares Out. | 391,460,000 |
| Website | standardbio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 389 |
| Revenue | $20.1M |
| Gross Profit | $10.5M |
| Net Income | -$26.8M |
| Free Cash Flow | -$82.6M |
| Total Assets | $627.2M |
| Total Liabilities | $87.2M |
| Equity | $540.0M |
About Standard BioTools Inc
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Standard BioTools Inc is a publicly traded company under the ticker symbol LAB on the NASDAQ NMS - GLOBAL MARKET, operating in the Life Sciences Tools & Services industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-09-01)